Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
SYN-010 21 mg
DRUG
2 trials
Sponsors
Theriva Biologics, Inc.
, Cedars-Sinai Medical Center
Conditions
Irritable Bowel Syndrome With Constipation
Irritable Bowel Syndrome With Constipation (IBS-C)
Phase 2
A Study of the Effect of SYN-010 on Subjects With IBS-C
Completed
NCT02495623
Theriva Biologics, Inc.
Irritable Bowel Syndrome With Constipation (IBS-C)
Start: 2015-06-30
End: 2015-11-30
Updated: 2018-11-27
Efficacy and Safety of SYN-010 in IBS-C
Terminated
NCT03763175
Cedars-Sinai Medical Center
Irritable Bowel Syndrome With Constipation
Start: 2018-12-24
End: 2020-10-09
Updated: 2022-07-13
Related Papers
Methanogens and Hydrogen Sulfide Producing Bacteria Guide Distinct Gut Microbe Profiles and Irritable Bowel Syndrome Subtypes
The American Journal of Gastroenterology
2022-09-06
142 citations
S499 Elevations in Breath Methane Are Associated With Lower Heart Rate: Post-Hoc Analysis of a Double Blind Randomized Control Trial
The American Journal of Gastroenterology
2021-10-01
SYN-010 Modified-Release Lovastatin Does Not Significantly Alter Lipid Parameters at Doses that Reduce Methane and Alleviate Symptoms in Patients Suffering Irritable Bowel Syndrome with Constipation (IBS-C)
The American Journal of Gastroenterology
2016-10-01
1 citations
Lovastatin lactone may improve irritable bowel syndrome with constipation (IBS-C) by inhibiting enzymes in the archaeal methanogenesis pathway.
2016-04-08
18 citations
Referee report. For: Lovastatin lactone may improve irritable bowel syndrome with constipation (IBS-C) by inhibiting enzymes in the archaeal methanogenesis pathway [version 1; referees: 1 approved with reservations]
Faculty of 1000 Research Ltd
2016-01-01
Referee report. For: Lovastatin lactone may improve irritable bowel syndrome with constipation (IBS-C) by inhibiting enzymes in the archaeal methanogenesis pathway [version 3; referees: 2 approved, 1 approved with reservations]
Faculty of 1000 Research Ltd
2016-01-01
Referee report. For: Lovastatin lactone may improve irritable bowel syndrome with constipation (IBS-C) by inhibiting enzymes in the archaeal methanogenesis pathway [version 2; referees: 2 approved with reservations]
Faculty of 1000 Research Ltd
2016-01-01